

AmideBio

Contact:

Dr. Misha Plam
AmideBio, LLC
President & CEO
misha.plam@amidebio.com
(303) 641-3669
<http://www.amidebio.com>

AmideBio to present at TIDES conference on May 24, 2011

Boulder, CO December 31, 2010

AmideBio, LLC announced today that Dr. Michael Stowell, Chief Technology Officer, AmideBio, LLC is going to present at TIDES conference:

“Functional Differences between Synthetic and Recombinant Amyloid Peptides”

“The AmideBio team investigated the functional differences between synthetic and AmideBio’s proprietary BioPure amyloid peptides using a combination of biophysical and cell assays. BioPure material has dramatically different properties than synthetically prepared material. The observed differences can be attributed to a combination of very minor N-1 and racemic peptide contaminants. These studies highlight the potential problems associated with synthetic peptides for both basic research and therapeutic applications.”

About AmideBio, LLC

AmideBio based in Boulder, CO is a biotechnology company focused on providing recombinant peptide research and clinical products for a diverse array of disease research and disease targets. AmideBio maintains a proprietary platform vector technology that addresses the challenges of historically difficult to manufacture peptides by providing products that are reliable (BioPure™), economical and incorporate environmentally sustainable practices. For more information please visit www.AmideBio.com

About TIDES conference

Oligonucleotide and Peptide® Technology and Product Development

May 22-25, 2011 * Hynes Convention Center * Boston, MA

A Case Study Approach to Overcoming

CMC Challenges of Drug Substance and Drug Product Development

TIDES is the only event that covers CMC manufacturing of peptide and oligo therapeutics in an in-depth manner, with the largest showcase of providers of services and technology critical to the field, and a proven track record of attendance that guarantees you a superior networking opportunity. It also includes in-depth programming on oligonucleotides therapeutics discovery, peptide discovery and development, and nucleic acids technologies for molecular diagnostics. For a complete agenda please visit:

www.IBCLifeSciences/TIDES